Two salvage HDR brachytherapy schedules produced similar outcomes in recurrent prostate cancer
In 223 previously irradiated patients, 3×10 Gy and 2×13 Gy salvage HDR brachytherapy produced similar disease control and late toxicity.
Latest research
Search the archiveSGRT-assisted DIBH reduced heart and LAD dose in left-sided breast radiotherapy
Across 52 studies, SGRT-assisted DIBH reduced mean heart dose by 1.21 Gy and LAD dose by 7.05 Gy versus free breathing.
Postoperative high-dose RT achieved strong local control in lacrimal gland adenoid cystic carcinoma
After surgery plus 66–70 Gy, only one of six patients recurred locally, while half developed distant metastases.
Comorbidity mattered more than chronological age after proton therapy for hepatocellular carcinoma
Age ≥75 did not independently predict outcomes after proton therapy for HCC, while CCI ≥3 was associated with more than threefold higher mortality.
Aggressive concurrent hypofractionation increased fatal toxicity in unresectable stage II–III NSCLC
Across 26 studies, fatal toxicity clustered when BED10 >100 Gy was delivered to the whole tumor with concurrent platinum chemotherapy.
Cardiac dose patterns and early ECG changes differed by breast cancer laterality
Left-sided breast IMRT was linked to more repolarization changes, while right-sided treatment produced predominantly rhythm abnormalities.
Two-week PACTUS radiotherapy showed feasibility in frail patients with anal cancer
PACTUS 40 Gy/10 produced 30-month median survival in 28 selected frail patients, but incomplete response and toxicity data limit efficacy conclusions.
Deep learning could provide a second-check for prostate pelvic nodal contours
AI pelvic nodal contours achieved a Dice score of 0.79 on withheld prostate RT cases but retained localized boundary disagreements.
Heart-base optimization substantially reduced cardiac substructure dose in distal esophageal RT
Heart-base-optimized IMRT/VMAT reduced cardiac avoidance area mean dose by about 6 Gy without compromising target coverage.
Simulation-free VMAT preserved delivered dose for palliative bone radiotherapy
Diagnostic CT-based VMAT preserved PTV D95 at 99.6% of planned dose across 30 palliative bone RT plans.
Brachytherapy-integrated hyperthermia remains technically feasible but clinically unproven
Two randomized trials failed to show benefit from brachytherapy-integrated hyperthermia, while inadequate thermal measurement remains a major barrier to clinical validation.
Proton RBE rose sharply beyond the Bragg peak in pancreatic cancer cells
In two PDAC cell lines, measured proton RBE remained near 1.0 through the Bragg peak but rose as high as 6.1 distally.
Iridium-192 remains the best-supported HDR source for breast brachytherapy
Iridium-192 has the strongest long-term breast brachytherapy evidence; cobalt-60 is dosimetrically comparable, while ytterbium-169 remains clinically unvalidated.
Ultracentral lung SBRT produced more grade 3 toxicity than central SBRT
Grade 3 toxicity was 16.7% for ultracentral versus 8.7% for central lung tumors, with no grade ≥4 events in this real-world cohort.
Proton SBRT achieved 77% two-year local control in high-risk lung tumors
In a prospective proton registry enriched for ultracentral, large, and re-irradiated lung tumors, two-year local control was 77% with no grade ≥3 toxicity.